SELLAS Life Sciences Group, Inc. — Director's Dealing 2010

Jan 19, 2010

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RXI PHARMACEUTICALS CORP (RXII)
CIK: 0001390478
Period of Report: 2010-01-14

Reporting Person: Hillsberg Sanford (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2010-01-14	Stock Option	$5.66	A	50000	Acquired	2020-01-14	Common Stock (50000)	Direct

Footnotes

F1: Granted pursuant to the RXi Pharmaceuticals Corporation 2007 Incentive Plan.

F2: Per share.

F3: The options will vest in equal quarterly installments of 12,500 on each of March 31, 2010, June 30, 2010, September 30, 2010 and December 31, 2010.